​

Kymera Therapeutics (KYMR) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

KYMR Stock Forecast

Kymera Therapeutics (KYMR) stock forecast, based on 23 Wall Street analysts, predicts a 12-month average price target of $66.25, with a high of $75.00 and a low of $60.00. This represents a 8.87% increase from the last price of $60.85.

$25 $35 $45 $55 $65 $75 High: $75 Avg: $66.25 Low: $60 Last Closed Price: $60.85

KYMR Stock Rating

Kymera Therapeutics stock's rating consensus is Buy, based on 23 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 20 Buy (86.96%), 3 Hold (13.04%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 23 3 20 0 Strong Sell Sell Hold Buy Strong Buy

KYMR Price Target Upside V Benchmarks

TypeNameUpside
StockKymera Therapeutics8.87%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts3613
Avg Price Target$68.67$67.67$62.15
Last Closing Price$60.85$60.85$60.85
Upside/Downside12.85%11.21%2.14%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 25616---22
Sep, 25416---20
Aug, 25416---20
Jul, 25416---20
Jun, 253143--20
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 22, 2025Jeet MukherjeeBTIG$75.00$58.3228.60%23.25%
Oct 01, 2025Oppenheimer$63.00$56.6011.31%3.53%
Sep 30, 2025Truist Financial$68.00$58.9315.39%11.75%
Sep 18, 2025H.C. Wainwright$70.00$50.8737.61%15.04%
Sep 16, 2025Barclays$60.00$48.7823.00%-1.40%
Sep 16, 2025Brian AbrahamsRBC Capital$70.00$48.2745.02%15.04%
Jun 27, 2025Jeff JonesOppenheimer$53.00$44.1220.13%-12.90%
Jun 26, 2025Jeet MukherjeeBTIG$59.00$46.4726.96%-3.04%
Jun 25, 2025Kelly ShiJefferies$64.00$46.2138.50%5.18%
Jun 03, 2025Michael SchmidtGuggenheim$60.00$43.5837.68%-1.40%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 22, 2025BTIGBuyBuyhold
Oct 17, 2025CitigroupBuyBuyhold
Oct 01, 2025OppenheimerOutperformOutperformhold
Sep 18, 2025H.C. WainwrightBuyBuyhold
Sep 16, 2025BarclaysOverweightinitialise
Sep 16, 2025RBC CapitalOutperforminitialise
Jun 27, 2025OppenheimerOutperformOutperformhold
Jun 26, 2025H.C. WainwrightBuyBuyhold
Jun 26, 2025BTIGBuyBuyhold
Jun 25, 2025JefferiesBuyBuyhold

Financial Forecast

EPS Forecast

$-9 $-8 $-7 $-6 $-5 $-4 $-3 $-2 $-1 $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.53$-2.04$-2.82$-2.52$-2.98----
Avg Forecast$-1.44$-1.86$-2.90$-2.64$-2.82$-3.06$-3.54$-3.57$-2.90
High Forecast$-0.44$-0.57$-0.64$-1.81$-2.15$-1.42$-2.49$-2.30$-0.03
Low Forecast$-3.18$-4.13$-7.72$-3.11$-3.15$-4.14$-5.73$-4.68$-8.26
Surprise %75.69%9.68%-2.76%-4.55%5.67%----

Revenue Forecast

$0 $90M $180M $270M $360M $450M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$34.03M$72.83M$46.83M$78.59M$47.07M----
Avg Forecast$42.01M$83.71M$50.19M$69.37M$53.87M$68.16M$63.62M$88.05M$181.58M
High Forecast$81.32M$162.04M$114.40M$118.35M$107.40M$170.65M$64.51M$89.94M$439.66M
Low Forecast$19.65M$39.15M$20.17M$39.77M$42.96M$18.28M$62.72M$86.16M$43.53M
Surprise %-18.99%-12.99%-6.70%13.30%-12.62%----

Net Income Forecast

$-500M $-400M $-300M $-200M $-100M $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-43.95M$-98.00M$-151.83M$-146.96M$-223.86M----
Avg Forecast$-83.85M$-78.75M$-127.85M$-146.96M$-167.47M$-162.27M$-319.20M$-203.93M$-169.39M
High Forecast$-25.83M$-63.00M$-102.28M$-117.57M$-125.71M$-83.08M$-145.22M$-134.43M$-1.97M
Low Forecast$-185.85M$-94.50M$-153.42M$-176.35M$-184.14M$-241.47M$-334.37M$-273.43M$-482.36M
Surprise %-47.59%24.43%18.76%-33.67%----

KYMR Forecast FAQ

Is Kymera Therapeutics stock a buy?

Kymera Therapeutics stock has a consensus rating of Buy, based on 23 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 20 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Kymera Therapeutics is a favorable investment for most analysts.

What is Kymera Therapeutics's price target?

Kymera Therapeutics's price target, set by 23 Wall Street analysts, averages $66.25 over the next 12 months. The price target range spans from $60 at the low end to $75 at the high end, suggesting a potential 8.87% change from the previous closing price of $60.85.

How does Kymera Therapeutics stock forecast compare to its benchmarks?

Kymera Therapeutics's stock forecast shows a 8.87% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Kymera Therapeutics over the past three months?

  • October 2025: 27.27% Strong Buy, 72.73% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 20.00% Strong Buy, 80.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 20.00% Strong Buy, 80.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Kymera Therapeutics’s EPS forecast?

Kymera Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-3.06, marking a 2.68% increase from the reported $-2.98 in 2024. Estimates for the following years are $-3.54 in 2026, $-3.57 in 2027, and $-2.9 in 2028.

What is Kymera Therapeutics’s revenue forecast?

Kymera Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $68.16M, reflecting a 44.81% increase from the reported $47.07M in 2024. The forecast for 2026 is $63.62M, followed by $88.05M for 2027, and $181.58M for 2028.

What is Kymera Therapeutics’s net income forecast?

Kymera Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-162M, representing a -27.51% decrease from the reported $-224M in 2024. Projections indicate $-319M in 2026, $-204M in 2027, and $-169M in 2028.